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Fatigue is a common and disabling nonmotor symptom seen in Parkinson’s disease (PD). While deep brain stimulation surgery
(DBS) improves motor symptoms, it has also been associated with non-motor side eﬀects. To date no study has utilized
standardized instruments to evaluate fatigue following DBS surgery. Our objective was to determine the prevalence of fatigue
following DBS surgery in PD its impact on quality of life and explore predictive factors. We recruited 44 PD subjects. At least one
yearfollowingDBSplacement,weadministeredtheFatigueSeverityScale(FSS),theParkinson’sDiseaseQuestionnaire(PDQ-39),






symptoms seen in Parkinson’s disease (PD) with studies
showing a prevalence of moderate to severe fatigue in 33–
58% of PD patients [1]. Fatigue is reported by one-third of
patients as their most disabling symptom and is associated
with a worse quality of life [2, 3]. The cause of fatigue in PD
remains unclear. Fatigue is seen even in newly diagnosed PD
patients and does not correlate with motor symptoms, other
measures of disease severity, sleep dysfunction, or medica-
tion use [1–4]. While studies have shown depression to be
the variable most strongly and consistently associated with
fatigue in PD they also demonstrate that these symptoms are
frequently independent [5, 6]. Cognitive dysfunction is also
associated with fatigue in PD in some studies but is clearly
independent from fatigue in many patients [4, 7].
While deep brain stimulation surgery (DBS) has proven
to be an eﬀective treatment to address the motor symp-
toms/ﬂuctuations in PD, more recent literature has demon-
strated that DBS may also be associated with signiﬁcant non-
motor side eﬀects, including changes in speech, worsening
cognition, and negative mood states [8–11]. These non-
motor side eﬀects may limit the beneﬁt of DBS for some
patients,particularlyintermsofoverallqualityoflife(QOL).
Fatigue has been largely unexamined in this population,
but given the prevalence of other non-motor issues in this
population, the potential for adverse eﬀects on QOL is wor-
thy of further study. Funkiewiez and colleagues utilized the
Addiction Research Center Inventory (ARCI) questionnaire2 Parkinson’s Disease
Parkinson’s Disease to evaluate fatigue on and oﬀ of DBS
patients three months following surgery [12]. They observed
some improvement in momentary “fatigue” when subjects
were in their on-DBS state. However, it is unclear how their
measure of fatigue, designed to test the aﬀect of psychoactive
substances, relates to fatigue in PD, and whether the acute
on/oﬀ eﬀects are representative of the chronic eﬀects of long-
term DBS stimulation.
Todate,nostudyhasutilizedstandardizedfatigueinstru-
ments to evaluate the prevalence of fatigue or its impact
on HR QOL following DBS surgery. Our primary objectives
were to (1) determine the prevalence of clinically signiﬁcant
fatigue in PD patients who have undergone DBS surgery;
(2) determine the association of fatigue with health related
quality of Life (HR-QOL). We hypothesized that fatigue is
common following DBS and inversely associated with HR-
QOL. Exploratory aims were to (1) identify disease charac-
teristics, mood, or neuropsychological variables associated
with fatigue in this cohort; (2) identify whether any aspects
or preoperative testing predicted fatigue following DBS.
We hypothesized that depression and cognitive dysfunction
would be associated with fatigue in this population and also
predict fatigue following DBS when detected preoperatively.
2. Methods
The investigational protocol was approved by the University
of Florida Institutional Review Board. All participants gave
written informed consent.
2.1. Participants. Forty-four consecutive patients with PD
who were at least one year after DBS surgery, able to give
consent, and interested in participating in research were
recruited from the University of Florida Movement Disorder
Clinics and clinical research database from May 2006 to July
2007.
2.2. Procedure. All subjects completed the following ques-
tionnaires at the time of recruitment: the Fatigue Severity
Scale (FSS) [13], the Parkinson’s Disease Questionnaire
Quality of Life-39 (PDQ-39) [14], the Apathy Scale [15], the
Beck Anxiety Inventory (BAI) [16], and the Beck Depression
Inventory (BDI-II) [17]. These scales have all been validated
within the PD population [14, 18–21]. Moderate to severe
f a t i g u ew a sd e ﬁ n e da sas c o r eo f4o rg r e a t e ro nt h eF S S .
Disease severity was assessed using the Hoehn and Yahr
scale [22] and motor section of the Uniﬁed Parkinson’s
Disease Rating Scale (UPDRS) [23] in the on-DBS and On
medication state.
For our exploratory objectives, a substantial subset of
patients (N = 28) had additional data available through
our clinical research database collected within six months of
recruitment for the current study and also pre-operatively.
This data included the State Trait Anxiety Inventory [24],
and a standard battery of neuropsychological function: Mini
Mental Status Exam [25], Dementia Rating Scale-2 [26],
Weschler Abbreviated Scale of Intelligence [27], Wechsler
Adult Intelligence Scale III (test the digit span, and digit
symbol)[28],StroopColorandWordTest[29],TrailAandB
[30], Boston Naming test [31], Controlled Oral Word Asso-
ciationTest[32],CategoryFluencyTest[33],HopkinsVerbal
Learning Test-Revised [34], Weschler Memory Scale III [28],
Judgment of Line Orientation Test [35], Face Recognition
Test [36], and Benton Visual Retention Test [37]. Disease
severity was assessed preoperatively (on medications) using
the Hoehn and Yahr scale [22] and the motor section of the
UPDRS [23].
2.3. Statistical Analysis. Statistical analysis was performed
using SAS version 9.2 (SAS Inc., Cary, NC). Wilcoxon rank-
sum test was used to determine diﬀerences between groups.
Spearman’s correlation was performed to determine rela-
tionships between continuous variables. Chi-square test, or
Fisher exact test, was when appropriate used to assess the re-
lationship between categorical variables. Linear regression
models were used to assess the association of multiple var-
iables, including controlling for confounding variables. P
values <.05 were considered signiﬁcant.
3. Results
3.1. Prevalence of Fatigue and Characteristics of the High and
Low Fatigue Patients. Fifty-eight percent of subjects (95%
conﬁdence interval: 43–73%) had a score of 4 or greater
on the FSS. The mean FSS score for this cohort was 4.2
(SD 1.3). When subjects were divided into low (FSS < 4;
mean FSS 3.0, SD 0.6) and high (FSS ≥ 4; mean FSS 5.2,
SD 0.8) fatigue groups, signiﬁcant diﬀerences were found
only in anxiety (BAI 8.0 versus 15.9, P = 0.001) and quality
of life (PDQ 39 23.8 versus 33.0, P = 0.02) in low versus
high fatigue groups, respectively. Trends for diﬀerences were
also noted in depression (BDI 7.4 versus 12.0, P = 0.07)
and disease duration (17.1 versus 14.1yrs, P = 0.10).
Table 1 outlines these comparisons and summarizes group
demographic data.
3.2. Correlation of Fatigue with Quality of Life. FSS scores
were signiﬁcantly associated with the total score of the
PDQ 39 (r = 0.37, P = 0.01) as well as the majority
of PDQ subscales including mobility, emotional well-being,
social support, cognition, and bodily discomfort. See Table 2
for the correlation of fatigue with PDQ 39 subscores.
Linear regression models demonstrated that the association
between the FSS and PDQ 39 remained signiﬁcant even after
controllingforage,diseaseduration,andmotorseverity(FSS
F-value in model 9.83, P<0.01).
3.3. Correlation of Fatigue with Disease Severity, Mood, and
Neuropsychological Test Results. Fatigue was associated with
depression as measured by the BDI (r = 0.47, P = 0.01)
and anxiety as measured by the BAI (r = 0.49, P<0.01)
but not with apathy, age, disease duration, time since DBS,
the UPDRS (on or oﬀ), Hoehn and Yahr (on or oﬀ), anxiety
measured with State and Trait Anxiety Inventory (STAI), or
any neuropsychological test scores.Parkinson’s Disease 3
Table 1: Comparison of clinical characteristics in high and low fatigue patients. Data reported as mean (standard deviation).
Total (n = 44) Low fatigue (FSS < 4) (n = 19) High fatigue (FSS ≥ 4) (n = 25) P value
Age (years) 63.3 (10.0) 61.5 (11.4) 64.7 (8.8) 0.32
Gender (% male) 86% 84% 88% 0.71∗
DBS target
STN (30) STN (14) STN (16)
GPI (10) GPI (3) GPI (7) 0.59∗∗
VIM (4) VIM (2) VIM (2)
Disease duration (years) 15.5 (5.5) 17.1 (6.0) 14.1 (11.8) 0.10
Months after DBS 26.1 (20.9) 27.3 (25.8) 25.3 (12.4) 0.81
Hoehn and Yahr (on) 2.5 (0.7) 2.5 (0.5) 2.5 (0.7) 0.92
UPDRS motor (on) 28.1 (12.6) 26.9 (12.7) 28.9 (12.7) 0.64
FSS 4.2 (0.8) 3.1 (0.6) 5.1 (0.8) <0.0001
MMSE 27.8 (2.4) 28.2 (1.9) 27.2 (3.0) 0.25
BDI 9.2 (7.2) 7.4 (6.6) 12.0 (7.4) 0.07
BAI 12.2 (8.2) 8.0 (5.2) 15.9 (8.6) 0.001
Apathy Scale 13.2 (6.6) 11.7 (7.1) 14.4 (6.1) 0.20
PDQ 39 28.7 (13.9) 23.8 (12.0) 33.0 (14.2) 0.02
Wilcoxon test was used except for: ∗Chi Square test was used and ∗∗Fisher’s Exact Test was used.
BAI: Beck Anxiety Inventory; BDI: Beck Depression Inventory; DBS: deep brain stimulation; FSS: Fatigue Severity Scale; GPI: globus pallidus interna; MMSE:
Mini Mental State Examination; PDQ: Parkinson’s Disease Questionnaire; STN: subthalamic nucleus; UPDRS: Uniﬁed Parkinson’s Disease Rating Scale; VIM:
ventral intermediate nucleus of thalamus.
Table 2: Correlation of Fatigue Severity Scale with Parkinson Dis-
ease Questionnaire (PDQ) 39 subscores.




Activities of daily living 0.27 (0.08)
Emotional well-being 0.38 (0.01)∗
Stigma 0.16 (0.32)
Social support 0.20 (0.20)
Cognition 0.42 (0.006)∗∗
Communication 0.11 (0.50)
Bodily discomfort 0.49 (0.001)∗∗
∗Pvalue signiﬁcant <0.05; ∗∗Pvalue < 0.01.
3.4. Factors Predictive of Fatigue in PD Patients Who Have
Undergone DBS Surgery. Depression as measured by BDI
was the only preoperative measure associated with fatigue
(Spearman’s r = 0.48, P = 0.03). While there was a strong
correlation between pre and postoperative BDI scores (r =
0.68, P<0.01), preoperative BDI scores remained associated
with the FSS even when controlled for postoperative BDI
in a linear regression model (BDI F-value in model 4.64,
P = 0.05). There was no association between DBS target and
fatigue (see Table 1; Fisher exact test P>0.05), anxiety (as
measured by STAI only), apathy, or any neuropsychological
test scores.
4. Discussion
Fatigue is a common non-motor symptom following DBS
surgery and seems to signiﬁcantly impact HR-QOL. Our
ﬁnding of 58% prevalence among DBS subjects is on the
higher end of the range of previously reported fatigue
prevalence in PD subjects without DBS which have ranged
from 33–58% [1]. Our data suggest that fatigue may be
related to mood disturbances, and this ﬁnding may have
implications for future research into the causes of fatigue in
DBS subjects.
The association of depression and fatigue has been well
documented in PD patients [1, 38]. The correlation with
anxiety as measured by the BAI, however, has not been
reported. Given the high prevalence of both symptoms, it
is not surprising that there would be some comorbidity
between these two symptoms [39]. It should be noted,
however, that the State and Trait Anxiety Inventory failed
to show a signiﬁcant correlation with fatigue. This ﬁnding
suggested that part of this association may be related to test
factors, for instance the weight of somatic questions on the
BAI. It is also possible that certain types of anxiety disorders
(e.g., panic disorders which is better screened by the BAI)
may be more associated with fatigue and better measured by
certain scales [40]. Whether this association has relevance to
PD patients without DBS is unknown but worthy of further
study given the prevalence of both fatigue and anxiety in PD.
The lack of correlation between fatigue and apathy or
neuropsychological performance is notable. One prior inves-
tigation demonstrated a trend toward correlation between
fatigue and the Wisconsin Card Sorting task as well as a
signiﬁcant association with frontal hypometabolism on PET
[41] .As e c o n ds t u d ys u g g e s t e dt h a tM M S Es c o r e sw e r e
higher in subjects with greater fatigue, but this result may
have been confounded by other diﬀerences between high
and low MMSE groups [7]. Our ﬁndings may suggest that
fatigue arises independently of other neuropsychological
symptoms in patients following DBS. However, objective
testing speciﬁcally for mental fatigue may prove to be more4 Parkinson’s Disease
sensitive in investigating this possible association [42]. It
should also be noted that DBS patients are a highly selected
population to begin with and may not have suﬃcient
variability in cognitive measures to fully explore a potential
association with fatigue. Moreover, our sample size of
subjects with adequate neuropsychological results (N = 28)
is not suﬃcient to detect subtle associations, and testing
was often not performed at the time of other subjective
measurements but included if performed within a six month
window.
This study has several notable limitations, including its
relatively small size, lack of longitudinal data, capture of
several variables at disparate time points (e.g., neuropsycho-
logical test results), and lack of a control group. Regarding
our deﬁnition of fatigue, while the FSS has been widely
used to deﬁne clinically signiﬁcant fatigue in many diseases,
including in PD, there are clear diﬀerences between the
various subjective scales and even more so with objective
measures of fatigability [19, 42]. Importantly, as fatigue was
not assessed prior to DBS surgery, we cannot determine
whether DBS impacts fatigue in this population. Future
investigations should consider using a larger sample size,
assessing fatigue and other explanatory variables longitudi-
nally (particularly prior to DBS), assessing sleep, and having
a control group of PD patients on medical treatment.
4.1. Conclusions. Fatigue is common following DBS surgery
inPDandhasanegativeimpactonHRQOLofthepa-tients.
Fatigue in this population appears associated with depres-
sion and possibly anxiety but did not correlate with other
neuropsychological tests or disease characteristics. Future
research should investigate fatigue before and after DBS to
determine whether DBS impacts this important symptom.
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